Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2025
Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved PharmacokineticsXiaoyan Li, You Zhang, Jason C Mixdorf, et al.
JCI Insight|July 7, 2017
Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis modelNicholas A Zumwalde, Akshat Sharma, Xuequn Xu, et al.
Oncotarget|June 3, 2017
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replicationAndrea Bilger, Julie Plowshay, Shidong Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Viral response to chemotherapy in endemic burkitt lymphomaWeihua Tang, Paula Harmon, Margaret L Gulley, et al.
Plos Pathogens|August 21, 2018
An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse modelJames C Romero-Masters, Makoto Ohashi, Reza Djavadian, et al.
Plos Pathogens|April 15, 2024
Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in miceJillian A Bristol, Scott E Nelson, Makoto Ohashi, et al.
Plos Pathogens|November 8, 2021
ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cellsNicholas Van Sciver, Makoto Ohashi, Dhananjay M Nawandar, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2026
Epstein-Barr virus (EBV) infection causes human germinal center B cell-derived lymphomas in the absence of EBNA2 expressionChunyan Wang, Jillian A Bristol, Scott E Nelson, et al.
The Journal of Clinical Investigation|December 9, 2014
LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesisShi-Dong Ma, Xuequn Xu, Julie Plowshay, et al.
The Journal of Investigative Dermatology|October 26, 2012
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repairNeehar Bhatia, Tony Z Xiao, Kimberly A Rosenthal, et al.
Pageof 9